Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guilherme dos Anjos Camargo has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Role of Lignin in Encapsulation Technologies

    by Guilherme Dos Anjos Camargo, Stéfany Scalco, Lilian Fernanda Martins Do Amaral, Izabelli Cristiani Barcelar Zakaluk, Jaqueline Carneiro

  • Open Access

    Thymomodulin as an Immunomodulatory Agent in Animal Species: a Scoping Review on Animal Health Impacts, One Health Interfaces, and Translational Relevance

    by Marilu Swiech, Ketllin Bragnholo, Bruna Therly Ferreira Cunha, Jessica Mendes Nadal, Paulo Vitor Farago, Bill Jorge Costa, Guilherme dos Anjos Camargo

    Thymomodulin is a thymus-derived peptide preparation with immunomodulatory properties studied in experimental and veterinary contexts. Within a One Health framework, integrating animal, human, and environmental health, enhancing animal immunity is hypothesized to aid disease prevention, reduce zoonotic transmission, and decrease antimicrobial use. This scoping review mapped evidence on thymomodulin and comparable calf thymus extracts as immunomodulators in non-human animals from 2000 to 2025, evaluating their relevance for One Health strategies. A structured literature search (1 January 2000-31 December 2025) was conducted in PubMed, Scopus, Web of Science, and SciELO, supplemented by grey literature and patent searches. Peer-reviewed studies reporting immunological or clinical outcomes in non-human animals were included; human-only studies and those lacking immune or health endpoints were excluded. Across species, thymomodulin consistently modulated innate and adaptive immunity. In fish, dietary supplementation enhanced vaccine responsiveness, antibody titers, and survival after pathogen challenge. In rodents, thymomodulin restored immune function in immunosuppressed models and accelerated pathogen clearance. In companion animals, adjunct therapy improved clinical outcomes, including increased survival and faster remission in cats with disseminated sporotrichosis, as well as improved hematological parameters in immunocompromised animals. Evidence from poultry and swine suggests enhanced vaccine-induced immunity and maternal transfer of immune protection. Overall, thymomodulin acts as an immune normalizer, reinforcing host defenses under immune compromise. These immunological benefits could potentially reduce pathogen shedding and the need for antimicrobials indirectly; however, the evidence remains heterogeneous. Standardized clinical trials and field-based studies are needed to support translation into One Health practice.

  • Open Access

    Comparative Study of Azelaic Acid Peeling vs. Tranexamic Acid Microneedling for the Treatment of Melasma

    by Guilherme dos Anjos Camargo, Daniella Woinarovicz Menegheti, Leticia Simeoni Avais, Evelyn Assis de Andrade, Patrícia Mathias Döll Boscardin, Giovani Marino Favero

    Melasma is an acquired hyperpigmentation that is more common in women and mainly affects the face. It can significantly reduce quality of life due to its chronic nature and resistance to treatment. Objectives: This study aimed to compare the clinical efficacy of azelaic acid peeling and combined tranexamic acid microneedling in patients with melasma, evaluating the impact of these therapies on skin depigmentation. Methods: This was a prospective clinical trial with a split-face design, using a convenience sample. Patients were recruited and divided into two groups for comparative treatment. Microneedling with 4 mg/mL tranexamic acid was applied to the right hemiface and 30% azelaic acid peeling to the left hemiface. The protocol included five sessions with a 15-day interval. Photographic records were taken before treatment, in the fifth session, and 15 days after the last session. The Melasma Area and Severity Index (MASI) and non-parametric tests were used to analyze the results. Results: The study included 10 patients, of whom 9 completed the treatment. The average age was 42 years. The most common skin phototype was type III (50%) and the predominant locations were the central facial area, forehead, and cheeks (55.6%). The photographic evaluation and MASI showed a significant improvement on both sides of the face, with the final values better than the initial ones. It was possible to observe that the azelaic acid peeling showed a significant whitening after the fourth session when compared to the other method. Conclusions: The clinical study of hemifaces concluded that both the azelaic acid peeling and microneedling with tranexamic acid are effective in the treatment of melasma, with the azelaic acid peeling showing results after the fourth session. Further studies with larger, randomized samples are recommended.


  • Open Access

    Blackberry (Rubus spp. Xavante Cultivar) Oil-Loaded PCL Nanocapsules: Sustainable Bioactive for In Vitro Collagen-Boosting Skincare

    by Daniela F. Maluf, Brenda A. Lopes, Mariana D. Miranda, Luana C. Teixeira, Ana P. Horacio, Amanda Jansen, Madeline S. Correa, Guilherme dos Anjos Camargo, Jessica Mendes Nadal, Jane Manfron, et al.

    Background: Blackberry seed oil (BSO), obtained from Rubus spp. Xavante cultivar via supercritical CO2 extraction, contains bioactive lipids and antioxidants, but its cosmetic application is limited by poor solubility and stability. Nanoencapsulation with poly(ε-caprolactone) (PCL) can overcome these limitations. Methods: BSO was characterized by Ultra-High-Performance Liquid Chromatography coupled with electrospray ionization quadrupole time-of-flight mass spectrometry and incorporated into PCL nanocapsules (NCBSO) using the preformed polymer deposition method. Physicochemical properties, stability (at 4 °C, room temperature, and 37 °C for 90 days), cytotoxicity, and collagen production were assessed in human fibroblasts. Additionally, a predictive in silico analysis using PASS Online, Molinspiration, and SEA platforms was performed to identify the bioactivities of major BSO compounds related to collagen synthesis, antioxidant potential, and anti-aging effects. Results: NCBSO showed a nanometric size of ~267 nm, low polydispersity (PDI < 0.2), negative zeta potential (−28 mV), and spherical morphology confirmed by FE-SEM. The dispersion remained stable across all tested temperatures, preserving pH and colloidal properties. In particular, BSO and NCBSO at 100 µg.mL−1 significantly enhanced in vitro collagen production by 170% and 200%, respectively, compared to untreated cells (p < 0.01). Superior bioactivity was observed for NCBSO. The in silico results support the role of key compounds in promoting collagen biosynthesis and protecting skin structure. No cytotoxic effects were achieved. Conclusions: The nanoencapsulation of BSO into PCL nanocapsules ensured formulation stability and potentiated collagen production. These findings support the potential of NCBSO as a promising candidate for future development as a collagen-boosting cosmeceutical.

  • Open Access

    Blackberry (Rubus spp. Xavante Cultivar) Oil-Loaded PCL Nanocapsules: A Sustainable Bioactive for Collagen-Boosting Skincare

    by Daniela F. Maluf, Brenda A. Lopes, Mariana D. Miranda, Luana C. Teixeira, Ana P. Horacio, Amanda Jansen, Madeline S. Correa, Guilherme dos Anjos Camargo, Jessica Mendes Nadal, Jane Manfron, et al.

    (1) Background: Blackberry seed oil (BSO), obtained from Rubus spp. Xavante cultivar via supercritical CO₂ extraction, contains bioactive lipids and antioxidants, but its cosmetic application is limited by poor solubility and stability. Nanoencapsulation with poly(ε-caprolactone) (PCL) can overcome these limitations. (2) Methods: BSO was characterized by UHPLC–ESI–Q-TOF–MS and incorporated into PCL nanocapsules (NCBSO) using the preformed polymer deposition method. Physicochemical properties, stability (at 4 °C, room temperature, and 37 °C for 90 days), cytotoxicity, and collagen production were assessed in human fibroblasts. (3) Results: NCBSO showed nanometric size (~267 nm), low polydispersity (PDI < 0.2), negative zeta potential (−28 mV), and spherical morphology confirmed by FE-SEM. The dispersion remained stable across all tested temperatures, preserving pH and colloidal properties. In particular, BSO and NCBSO at 100 µg.mL-1 significantly enhanced collagen production by 170% and 200%, respectively, compared to untreated cells (p < 0.01). Superior bioactivity was observed for NCBSO. No cytotoxic effects were achieved. (4) Conclusions: The nanoencapsulation of BSO into PCL nanocapsules ensured formulation stability and potentiated collagen production. NCBSO may be further used as a novel cosmeceutical for collagen-boosting skincare.

  • Open Access

    Lutein Polymeric Nanocapsules for Skin: Development and Characterization

    by Thais Franceni de Oliveira, Brenda Alves Lopes, Marcela Novak Gummy, Elton Kazmierczak, Maycon Hudson Contador, Romaiana Picada Pereira, Guilherme dos Anjos Camargo, Paulo Vitor Farago, Patrícia Mathias Döll-Boscardin

    Lutein, a potent carotenoid antioxidant, shows promise for anti-aging applications. However, its vulnerability to light, heat, and oxygen, coupled with poor water solubility, hinders skin penetration and bioavailability. Nanostructured systems offer a solution to enhance stability and permeation. Our objective was to develop, characterize, and assess the cytotoxicity and antioxidant activity of polymeric nanocapsules containing lutein, using poly(ɛ-caprolactone) (PCL). Nanocapsules were synthesized via preformed polymer interfacial deposition method and characterized using dynamic light scattering (DLS), electrophoretic mobility, and pH. Morphology was examined using field emission scanning electron microscopy (FESEM). X-ray diffraction (XRD) indicated the crystalline structures while Fourier-transform infrared spectra (FTIR) provided information on the chemical bonds between the drug and polymer. Antioxidant activity was measured using FRAP, DPPH, and ABTS assays, while cytotoxicity was evaluated on 3T3 fibroblasts. Lutein encapsulation within PCL nanocapsules yielded spherical particles around 300 nm, with low polydispersity and zeta potential exceeding -30 mV. The pH ranged from 4.57 ± 0.03 to 5.42 ± 0.065. XRD suggested molecular dispersion of the lutein and the polymer. FTIR demonstrated the absence of chemical bonds between lutein and PCL. Ambient and 4 °C temperatures preserved nanosystems' characteristics for 30 days. Enhanced antioxidant activity was observed in encapsulated lutein, shown by FRAP, DPPH, and ABTS assays. Results indicated that lutein nanoparticles exhibited good biocompatibility and no cytotoxicity at concentrations ranging from 61.87 μg/mL to 7.73 μg/mL. These findings emphasize the potential of lutein-loaded PCL nanocapsules for skin delivery, providing stability and antioxidant efficacy.

  • Open Access

    Development and Validation of an RP-HPLC/DAD Method for Luteolin Quantification in Novel Hydroxyapatite Nanocomposites

    by Amanda Jansen, Vinícius Monteiro Schaffka, Cynthia Maria Schnekenberg Egg, Guilherme dos Anjos Camargo, Paulo Vitor Farago

    Calcium hydroxyapatite (HAp) is widely used in medical and aesthetic fields for bone repair and dermal applications. Luteolin (LUT), a flavonoid with anti-inflammatory and antioxidant properties, may enhance the therapeutic potential of HAp for collagen production into the skin. The main aim of this paper was to develop and validate a simple and reliable RP-HPLC/DAD method for quantifying LUT in HAp nanocomposites. The synthesis of hydroxyapatite nanoparticles (n-HAp) was performed via precipitation method. To obtain the novel nanocomposites, n-HAp was associated with LUT by the wet method using ethanol into a SpeedMixer®, followed by drying into an oven at 35ºC for 48 hours. The RP-HPLC/DAD method was developed for quantifying the LUT incorporation efficiency. The validation parameters assessed included selectivity, linearity, limits of quantification (LOQ) and detection (LOD), precision, accuracy, robustness, and sample stability. The novel nanocomposites n-Hap-LUT were successfully prepared using the proposed method. The incorporation efficiency demonstrated high values of 82.90% and 95.16% for nHAp-LUT samples. Thus, the RP-HPLC/DAD method was appropriate for quantifying LUT in novel dermal aesthetic products for collagen production and may be further used for design and quality control of novel collagen biostimulation technologies.


  • Open Access

    Novel Formula Containing Melatonin Precursors for Sleep Regulation

    by Angelo César D´uRso Panerari, Milton de Paula Júnior, Mariane Zancanaro Gallina, Maria Júlia Rosa Braz Dias, Daniele Fante de Oliveira, Emanuella Regina Vilhena da Silva, Guilherme dos Anjos Camargo, Guilherme Moreira de Caetano Pinto, Bruno Pedroso, Giovani Marino Favero

    This study aimed to assess the efficacy of a new formulation containing melatonin precursors in patients with sleep disorders. Thirty-six individuals were divided into two groups: one receiving the new formulation and the other a placebo, for 30 days. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI) questionnaire before and after intervention. It showed significant improvements in sleep quality, including reduced time to fall asleep, fewer nighttime awakenings, and higher overall satisfaction, in the group receiving the new formulation. However, some aspects, such as difficulty staying awake during the day, did not show significant differences. Comparison between groups revealed initial disparities in sleep-related aspects, which narrowed after intervention in the formulation supplement group. These findings suggest that the new formulation may effectively improve sleep quality, emphasizing the need for further research to comprehensively understand its impact on sleep and overall health.


  • Computational simulation on the study of Tacrolimus and its improved dermal retention using Poly(Ԑ-caprolactone) nanocapsules

    by Paulo Vitor Farago, Guilherme dos Anjos Camargo, Matheus Benedito Mendes, Betina Christi Semianko, Alexandre Camilo Junior, Daniele Toniolo Dias, Lucas Stori de Lara, Andressa Novatski, Jessica Mendes Nadal, Jane Manfron, et al.


  • Open Access

    Preparation, Characterization and Stability Study of Eugenol-Loaded Eudragit RS100 Nanocapsules for Dental Sensitivity Reduction

    by Ana Paula Vilela, Leandro Ferreira, Patrícia Bubna Biscaia, Karine Letícia da Silva, Flávio Luís Beltrame, Guilherme dos Anjos Camargo, Marcia Rezende, Jessica Mendes Nadal, Andressa Novatski, Jane Manfron, et al.

    Eugenol is a phenolic compound with numerous biological activities. It is widely used in dentistry to treat toothache and pulpitis. In particular, eugenol may be used for tooth whitening procedures to minimize dental sensitivity in patients. However, eugenol has some disadvantages such as its volatility, its photosensitivity, and immediate effect, which can be avoided by using pharmaceutical nanotechnology. The aim of the present study was to obtain, characterize, quantify, and evaluate the physicochemical stability of eugenol-loaded Eudragit RS100 nanocapsules. The nanocapsules (NCs) were prepared by interfacial deposition of the preformed polymer method. The NCs were characterized through morphological and spectroscopic studies. The encapsulation efficiency was achieved by quantifying the non-encapsulated eugenol using a previously developed and validated analytical method. The physicochemical stability of NCs was assessed at predetermined time intervals for 90 days after preparation. The nanocapsules were successfully prepared by the chosen method and had a predominantly spherical shape with a smooth surface. The mean size, the polydispersion index, and the zeta potential were in agreement to literature data. Infrared spectra ensured that the nanoencapsulation process did not result in chemical reactions between the drug and the polymer. The formulations showed encapsulation efficiency higher than 90% and remained stable after 60 days of preparation. Thus, eugenol-loaded Eudragit RS100 nanocapsules may be further considered as an alternative formulation for dental sensitivity in order to provide a controlled release, a decreased toxicity, and a better dental sensitivity relief.